Legend Biotech (LEGN) News and press releases

Earnings Scheduled For November 20, 2023

20 Nov 23

Earnings

Companies Reporting Before The Bell • Greenland Technologies (NASDAQ:GTEC) is projected to report quarterly earnings at $0.05 per share on revenue of $24.26 million.

Legend Biotech Q3 EPS $(0.17) May Not Be Comparable To $(0.65) Estimate, Sales $96.01M Miss $97.28M Estimate

20 Nov 23

Earnings, News

Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.65) by 73.85 percent. This is a 34.62 percent increase over losses of $(0.26) per share from

HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $87

15 Nov 23

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Mitchell Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price target from $86 to $87.

Legend Biotech Announces Exclusive, Global License Agreement For Certain CAR-T Therapies Targeting DLL3

13 Nov 23

Biotech, News, General

The deal with Novartis seeks to advance Legend Biotech's autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies targeting Delta-like ligand protein 3 (DLL3), using the Novartis

Positive Outlook On Johnson & Johnson's Partner Legend Biotech: Analyst Confident On Blood Cancer Drug

18 Oct 23

Analyst Color, Biotech, News, Health Care, Analyst Ratings, Trading Ideas, General

Legend Biotech Corporation's (NASDAQ: LEGN) partner, Johnson & Johnson (NYSE: JNJ), reported Q3 Carvykti revenues of $152 million,

Analyst Ratings for Legend Biotech

18 Oct 23

Analyst Ratings

Barclays Maintains Overweight on Legend Biotech, Raises Price Target to $93

18 Oct 23

News, Price Target, Analyst Ratings

Barclays analyst Gena Wang maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target from $92 to $93.

HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $86

18 Oct 23

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Mitchell Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price target from $85 to $86.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Legend Biotech Corporation – LEGN

4 Dec 23

News, Legal, Press Releases

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Legend Biotech Corporation ("Legend" or the "Company") (NASDAQ:LEGN). Such investors are advised to contact

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Legend Biotech Corporation - LEGN

28 Nov 23

Press Releases

NEW YORK, Nov. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Legend Biotech Corporation ("Legend" or the "Company") (NASDAQ:LEGN). Such investors are advised to

Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights

20 Nov 23

Press Releases

Legend Biotech Corporation (the "Company" or Legend Biotech), through its wholly owned subsidiary, Legend Biotech Ireland Limited, entered into an exclusive, global license agreement with Novartis Pharma AG. The

Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3

13 Nov 23

Press Releases

The deal with Novartis seeks to advance Legend Biotech's autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies targeting Delta-like ligand protein 3 (DLL3), using the Novartis

Legend Biotech to Host Investor Conference Call on Third-Quarter Results

7 Nov 23

Press Releases

Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, will host a conference call for

Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting

2 Nov 23

Press Releases

Two oral presentations and five poster presentations at ASH Annual Meeting exhibit new and updated data in the clinical development program for ciltacabtagene autoleucel (cilta-cel) Patient-reported outcomes (PROs)